First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Tyrosine kinase inhibitors (TKIs) are standard first-line treatments for metastatic renal cell carcinoma (mRCC).
• Sunitinib and pazopanib have demonstrated superior efficacy compared to older therapies in phase III trials.
• No direct comparative data existed between sunitinib and pazopanib for first-line mRCC treatment prior to the COMPARZ study.

Purpose of the Study:

• To compare the efficacy and safety of pazopanib versus sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
• To determine if pazopanib is non-inferior to sunitinib in treating mRCC.

Main Methods:

• The COMPARZ study was a non-inferiority, randomized phase III trial.
• Patients with previously untreated mRCC received either pazopanib or sunitinib.
• Progression-free survival (PFS) and overall survival (OS) were key endpoints, alongside safety assessments.

Main Results:

• The study met its primary endpoint, demonstrating non-inferiority of pazopanib compared to sunitinib regarding progression-free survival.
• Overall survival and objective response rates were similar between the two treatment arms.
• Safety profiles were comparable, with expected toxicities for each drug.

Conclusions:

• Pazopanib is a viable and effective alternative to sunitinib for first-line treatment of mRCC.
• The choice between pazopanib and sunitinib may depend on individual patient factors and physician preference.
• Further discussion on study design and potential confounding factors is warranted for complete interpretation.